Back to top
more

Incyte (INCY)

(Real Time Quote from BATS)

$58.50 USD

58.50
539,656

-0.07 (-0.12%)

Updated Jun 5, 2024 10:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Incyte (INCY) Up 1.5% Since Last Earnings Report?

by Zacks Equity Research

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down

by Zacks Equity Research

AstraZeneca (AZN) announced that Imfinzi as a monotherapy or in combination with tremelimumab failed to improve overall survival in first-line NSCLC. The combination had also failed to improve progression free survival last year.

Merck's Keytruda Improves Survival in Esophageal Cancer Study

by Zacks Equity Research

Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer.

Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer

by Zacks Equity Research

Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.

Agenus (AGEN) Q3 Loss Wider Than Expected, Pipeline in Focus

by Zacks Equity Research

Agenus (AGEN) reports a wider third-quarter loss. Revenues earned from collaborations exceeded expectations.

Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View

by Zacks Equity Research

Incyte (INCY) third-quarter earnings and revenues miss estimates but rise year over year.

Incyte (INCY) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of -5.00% and -3.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q3 results on Oct 30.

Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod

by Zacks Equity Research

Earnings releases and key data-read outs were the key developments in the biotech sector last week.

Incyte (INCY) Q3 Earnings Preview: What to Know Ahead of the Release

by Zacks Equity Research

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales

by Zacks Equity Research

Incyte's (INCY) performance is likely to be strong due to rising demand of lead drug, Jakafi.

5 Reasons Why Investors Should Bet on Merck (MRK) Stock

by Zacks Equity Research

Here are some reasons why investors may consider putting their money into Merck (MRK) stock.

Agenus Receives Milestone Payment of $5 Million from Incyte

by Zacks Equity Research

Agenus (AGEN) receives a milestone payment of $5 million from Incyte on the initiation of a phase I study of INCAGN2385.

    Merck Gets Priority Review for Yet Another Keytruda sBLA

    by Zacks Equity Research

    Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets FDA's priority review. If approved, it will expand the eligible patient population.

      Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars

      by Zacks Equity Research

      Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.

        Incyte, Foundation Medicine Partner for Companion Diagnostics

        by Zacks Equity Research

        Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.

          Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe

          by Zacks Equity Research

          Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting.

            Merck's Keytruda Gets Priority Review for Rare Skin Cancer

            by Zacks Equity Research

            Merck's (MRK) sBLA for Keytruda to expand its label for a rare form of skin cancer gets priority review from FDA.

              Why Is Incyte (INCY) Up 12.9% Since Last Earnings Report?

              by Zacks Equity Research

              Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion

                by Zacks Equity Research

                Merck (MRK) gets FDA approval to include overall survival data from a key late-stage lung cancer study, KEYNOTE-189 study, on the label of its PD-L1 inhibitor, Keytruda.

                  Agenus (AGEN) Delivering Well on Its Pipeline Candidates

                  by Zacks Equity Research

                  We have issued an updated report on Agenus (AGEN) highlighting updates on its pipeline candidates.

                    Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release

                    by Zacks Equity Research

                    Merck's (MRK) stock is up 4.2% since announcement of earnings in July. Let us have a look at the reasons for the same.

                      Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat

                      by Zacks Equity Research

                      Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.

                        Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2

                        by Zacks Equity Research

                        Incyte's (INCY) Q2 results were a mixed bag with earnings missing estimates, while revenues beating the same with growth in Jakafi's sales. A milestone payment from Eli Lilly boosted sales as well.

                          Incyte (INCY) Lags Q2 Earnings Estimates

                          by Zacks Equity Research

                          Incyte (INCY) delivered earnings and revenue surprises of -13.33% and 12.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?